Head-To-Head Survey: Arcturus Therapeutics (NASDAQ:ARCT) versus ImageneBio (NASDAQ:IMA)

ImageneBio (NASDAQ:IMA) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ImageneBio and Arcturus Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2	0	1	1	2.25
Arcturus Therapeutics	1	3	6	1	2.64

ImageneBio presently has a consensus price target of $29.00, suggesting a potential upside of 533.19%. Arcturus Therapeutics has a consensus price target of $22.43, suggesting a potential upside of 63.71%. Given ImageneBio’s higher possible upside, equities research analysts clearly believe ImageneBio is more favorable than Arcturus Therapeutics.

Institutional & Insider Ownership

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ImageneBio and Arcturus Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800,000.00	64.98	-$45.35 million	($4.58)	-1.00
Arcturus Therapeutics	$82.03 million	4.75	-$65.78 million	($3.31)	-4.14

ImageneBio has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ImageneBio has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.48, meaning that its share price is 148% more volatile than the S&P 500.

Profitability

This table compares ImageneBio and Arcturus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

About ImageneBio

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.